Disclosed herein are veterinary compositions including imidacloprid or an analogue thereof; a pyrethroid; a solvent selected from the group consisting of N-methyl pyrrolidone, N-ethyl pyrrolidone and mixtures thereof; and dimethyl sulfoxide. The veterinary compositions of the invention are useful in methods of controlling parasites on or within warm-blooded domesticated animals.

Provided herein are stable amlodipine oral liquid formulations. Also provided herein are methods of using amlodipine oral liquid formulations for the treatment of certain diseases including hypertension and Coronary Artery Disease (CAD).

Compositions and methods for the treatment of depression and psychoses in humans are disclosed. More particularly, the invention is directed to formulations containing antipsychotic and/or antidepressant medications and also containing an NMDAR antagonist. The present Invention Is also directed to methods tor the treatment of humans suffering from depression and other psychoses, including, schizophrenia, by administration of the inventive compositions in antidepressant and/or antipsychotic effective amounts.

A composition having an active compound contained within a microcapsule, the microcapsule having a wall comprising a polyurea formed by a polyisocyanate and a cross linking agent, the cross linking agent being the product of the reaction of a hydroxide salt with the copolymerization product of styrene and maleic anhydride. The active compound may be an agrochemical, in particular a herbicide or an insecticide. A process for the preparation of a microencapsulated active component including: providing an aqueous phase comprising a cross linking agent being the product of the reaction of a hydroxide salt with the copolymerization product of styrene and maleic anhydride; providing a first water-immiscible organic phase comprising an active ingredient to be encapsulated and a first polyisocyanate; dispersing the first organic phase in the aqueous phase; and allowing an interfacial polymerization reaction to occur at the interface of the organic phase and the aqueous phase to form a polyurea shell having the active component encapsulated therein.

A composition having an active compound contained within a microcapsule, the microcapsule having a wall comprising a polyurea formed by a polyisocyanate and a cross linking agent, the cross linking agent being the product of the reaction of a hydroxide salt with the copolymerization product of styrene and maleic anhydride. The active compound may be an agrochemical, in particular a herbicide or an insecticide. A process for the preparation of a microencapsulated active component including: providing an aqueous phase comprising a cross linking agent being the product of the reaction of a hydroxide salt with the copolymerization product of styrene and maleic anhydride; providing a first water-immiscible organic phase comprising an active ingredient to be encapsulated and a first polyisocyanate; dispersing the first organic phase in the aqueous phase; and allowing an interfacial polymerization reaction to occur at the interface of the organic phase and the aqueous phase to form a polyurea shell having the active component encapsulated therein.

Aniline compounds are provided which bind to CCR(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer.

The present invention relates to a method for identifying a polynucleotide encoding a polypeptide which confers herbicide tolerance to a plant by measuring photosynthetic quantum yield wherein an increase in the electron transport rate of the samples of the transformed plant as compared to the sample of the control plant is indicative for a herbicide tolerance conferring activity of said candidate polypeptide.

An analgesic and antipruritic pharmaceutical composition, including PF-05089771 shown as ##STR00001##
and PF-04885614 shown as ##STR00002##
An application of the analgesic and antipruritic pharmaceutical composition in the treatment of a disease in which both a voltage-gated sodium channel 1.7 (Na.sub.v1.7) and a voltage-gated sodium channel 1.8 (Na.sub.v1.8) are involved.

The present invention relates to stable liquid oral compositions of cyclophosphamide having extended stability, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by cyclophosphamide. The invention also relates to a kit comprising stable liquid oral compositions of cyclophosphamide.

The present invention is a glutamine compound having a high Z element attached via a ligand, which enters the mitochondrion and is subsequently exposed to ionizing radiation. When exposed to ionizing radiation, the present invention damages mitochondrial (as well as other) substructures such as mtDNA, the outer membrane, the inner membrane, cristae, ribosomes, etc., and causes the effective destruction of such mitochondrion. Tumorigenic cells without mitochondria cannot produce the energy they need to subsist and replicate, effectively starving them of energy and causing their destruction.